Document:

Omnibus Amendment to Loan Agreement

 Exhibit 10.38.1 
 OMNIBUS AMENDMENT REGARDING 
 LOAN AGREEMENT 
 This OMNIBUS AMENDMENT (this “Amendment”) dated December 21, 2009 is entered into by and between LFB Biotechnologies S.A.S. (the
“Purchaser”) and GTC Biotherapeutics, Inc. (the “Company”). 
 WHEREAS, in connection with the execution and
delivery of that certain Loan Agreement dated June 18, 2009 by and between the Purchaser and the Company (the “Loan Agreement”), the Company issued to the Purchaser a Promissory Note dated June 18, 2009 in the original principal
amount of Three Million Five Hundred Thousand Dollars ($3,500,000) (the “Note”); 
 WHEREAS, on the date hereof, the
Company has issued an Amended and Restated Promissory Note, (as further amended or otherwise modified from time to time, the “Amended Note”) that amends, restates, replaces and supersedes the Note in its entirety; and 
 WHEREAS, for the avoidance of doubt, the Company and the Purchaser desire to amend (i) the Loan Agreement, (ii) that certain
Amended and Restated Security Agreement by and between the Purchaser and the Company dated as of June 18, 2009 and effective as of December 22, 2008 with respect to certain matters, (iii) that certain Securities Purchase Agreement by
and between the Purchaser and the Company dated June 18, 2009, (iv) that certain Second Mortgage, Security Agreement and Fixture Filing executed by the Company dated December 22, 2008, as amended by Amendment to Mortgage, Security
Agreement and Fixture Filing dated June 18, 2009, and (v) any other documents and agreements related to the Loan Agreement, each as amended or otherwise modified from time to time (collectively the “Transaction Documents”) such
that each reference to the Note contained in each of the Transaction Documents is deemed to refer to the Amended Note; and 
 NOW, THEREFORE, in consideration for the mutual covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
 1. Amendment. Every reference contained in each of the Transaction Documents to the “Secured Note” shall be deemed
to be a reference to the Amended Note. 
 2. Counterparts. This Amendment may be executed in any number of counterparts
by original or facsimile signature, each such counterpart shall be an original instrument, and all such counterparts together shall constitute one and the same agreement. 
 [remainder left intentionally blank] 

 IN WITNESS WHEREOF, each of the undersigned hereby executes this Omnibus Amendment as of the
date first set forth above. 
  

			
	COMPANY:
	
	GTC BIOTHERAPEUTICS, INC.
		
	By:	 	/s/ John B. Green
	Title: John B. Green, Senior Vice President, Treasurer and Chief Financial Officer

  

			
	PURCHASER:
	
	LFB BIOTECHNOLOGIES S.A.S.
		
	By:	 	/s/ Christian Béchon
	 Christian Béchon
 President

 Signature Page to Omnibus Amendment 
 (Loan Agreement)Second Amendment to Mortgage Agreement

 Exhibit 10.40.1 
 When recorded return to: 
 Christopher J. Lhulier, Esq. 
 Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. 
 One Financial Center 
 Boston, MA 02111 
 SECOND AMENDMENT TO MORTGAGE, SECURITY AGREEMENT 
 AND FIXTURE FILING 

 THIS SECOND AMENDMENT TO MORTGAGE, SECURITY AGREEMENT AND FIXTURE FILING (this
“Amendment”) is made as of the 21st day
of December, 2009, by and between GTC BIOTHERAPEUTICS, INC., a Massachusetts corporation, formerly known as GENZYME TRANSGENICS CORPORATION, having an address of 175 Crossing Boulevard, Suite 410, Framingham, Massachusetts 01702 (the
“Grantor”), and LFB BIOTECHNOLOGIES S.A.S.U., having an address of 3, avenue des Tropiques, LES ULIS, 91940 Courtaboeuf - FRANCE (the “Grantee”). 
 W I T N E S S E T H    T H A T: 
 WHEREAS, the Grantor granted the Grantee a certain Second Mortgage, Security Agreement and Fixture Filing dated as of December 22, 2008
and recorded with the Registry of Deeds for Worcester County, Massachusetts on December 22, 2008 in Book 43614, Page 182 with respect to certain real property of Grantor located in the Towns of Charlton and Spencer, County of Worcester,
Commonwealth of Massachusetts and more particularly described therein and amended by that certain Amendment to Mortgage, Security Agreement and Fixture Filing dated as of June 18th, 2009 and recorded with the Registry of Deeds for Worcester
County, Massachusetts on June 22, 2009 in Book 44458, Page 375 (as amended, the “Existing Mortgage”), to secure, inter alia, certain indebtedness, obligations and liabilities of the Grantor to the Grantee; and

 WHEREAS, the parties hereto desire to further amend the Existing Mortgage in the manner as hereinafter set forth. 

NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereto hereby
agree as follows: 
 1. Recitals. The foregoing recitals are hereby incorporated by reference herein. 

 2. Amendments to the Existing Mortgage. The Existing Mortgage is hereby further
amended as follows: 
 (a) Section 1.1(a) of the Existing Mortgage is hereby further amended as follows: 
 The following definitions of “Secured Note”, “2006 Convertible Note” and “2008 Convertible Note” are hereby
amended and restated as follows: 
 ““Secured Note” means the Amended and Restated Promissory Note dated
June 18, 2009 and amended and restated as of December 21, 2009 executed by Grantor, payable to the order of Grantee, in the stated principal amount of Three Million Four Hundred Eighty-Three Thousand Six Hundred Eighty-Two and 88/100 Dollars
($3,483,682.88), which is scheduled to mature on January 1, 2012, as amended from time to time.” 
 ““2006
Convertible Note” means the Subordinated Convertible Note dated December 14, 2006, executed by Grantor, payable to the order of Grantee, in the stated principal amount of Two Million Five Hundred Fifty Eight Thousand Six Hundred Fifty
and 00/100 Dollars ($2,558,650.00), which is scheduled to mature on December 14, 2011, as amended from time to time.” 
 ““2008 Convertible Note” means the Amended and Restated Convertible Promissory Note dated on or about December 22, 2008 and amended and restated as of December 21, 2009 executed by Grantor, payable to the order of
Grantee, in the stated principal amount of Fifteen Million and 00/100 Dollars ($15,000,000.00), which is scheduled to mature on June 1, 2012, as amended from time to time.” 
 (b) The definition of “2009 Convertible Note” is hereby deleted in its entirety and all references to the 2009 Convertible Note in
the Existing Mortgage are likewise deleted in their entirety. 
 3. Ratification. The Grantor and the Grantee each agree
that, except as amended hereby, the Existing Mortgage shall remain in full force and effect and is in all other respects ratified and confirmed. The term “Mortgage” as used in the Existing Mortgage and any other documents or agreements
between the parties hereto which relate to the indebtedness secured by the Existing Mortgage shall refer, from and after the date hereof, to the Existing Mortgage as amended by this Amendment and as the same may from time to time be further amended,
supplemented, restated or otherwise modified. 
 4. Confirmation. The Grantor hereby confirms the grant to the Grantee of
the Existing Mortgage with MORTGAGE COVENANTS and upon the STATUTORY CONDITION and with the STATUTORY POWER OF SALE. 
 5.
Counterparts. This Amendment may be executed by the parties hereto in counterparts, each of which shall be deemed to be an original and all of which together shall constitute one and the same instrument. 
 *Balance of Page Intentionally Left Blank* 
  

 - 2 - 

 IN WITNESS WHEREOF, Mortgagor and Mortgagee have each caused this Second Amendment to
Mortgage, Security Agreement and Fixture Filing to be executed as an instrument under seal as of the day and year first written above. 
  

			
	Mortgagor:
	
	GTC BIOTHERAPEUTICS, INC.
		
	By:	 	/s/ John B. Green
		 	 John B. Green,
 Senior Vice
President, CFO and Treasurer

 Commonwealth of Massachusetts 
  

			
	Middlesex	 	County, ss.

 On this 21
st day of December, 2009, before me, the undersigned
notary public, personally appeared John B. Green, proved to me through satisfactory evidence of identification, being (check whichever applies):   ̈     driver’s
license or other state or federal governmental document bearing a photographic image,   ̈     oath or affirmation of a credible witness known to me who knows the above
signatory, or   ̈    my own personal knowledge of the identity of the signatory, to be the person whose name is signed above, and acknowledged the foregoing to be signed by
him voluntarily for its stated purpose, as the duly authorized signatory of GTC Biotherapeutics, Inc. 
  

			
	
	/s/ Susan Doucette
	Notary Public	 	
	My commission expires:	 	8/16/13
	Print Notary Public’s Name:	 	Susan A. Doucette
	Qualified in the Commonwealth of Massachusetts
	[Notary Seal]

 *
Signatures Continued on Next Page * 
 [Signature page to Second Amendment to Mortgage] 

			
	Mortgagee:
	
	LFB BIOTECHNOLOGIES, S.A.S.
		
	By:	 	/s/ Christian Béchon
		 	 Christian Béchon,
 President Directeur General

  
 [Signature page to Second Amendment to Mortgage]Services Agreement

					
		 	 Exhibit 10.42
  
 Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote such omissions.

  
 www.gtc-bio.com 

 

 

 SERVICES AGREEMENT 
  
  
 THESE TERMS AND CONDITIONS are agreed to as
of this 16th day of July, 2009 (the “Effective Date”) by and between GTC Biotherapeutics, Inc., a Massachusetts corporation with a business address at 175 Crossing Boulevard, Framingham, Massachusetts 01702 (“GTC”) and LFB
Biotechnologies S.A.S. a Sociétée par Actions Simplifiée, having offices at 3, avenue des Tropiques, es Ulis, 91940 Courtaboeuf, France (“LFB”). GTC and LFB are sometimes referred to herein individually as a
“Party” and collectively as the “Parties.” 
  
  

 

	1.	BACKGROUND 

 GTC and LFB
have agreed on terms and conditions, pursuant to which GTC will provide certain services for LFB’s benefit 
  

	2.	CERTAIN MANAGEMENT RELATED SERVICES 

 This Agreement establishes all of the terms and conditions under which the GTC shall provide certain services to LFB (“Services”). In general it is expected that LFB will utilize the following
resources of GTC: 
  

	 	2.1	Services 

 LFB may utilize
the following functions at GTC (“Services”): 
  

	 	2.1.1	GTC’s purchasing of laboratory equipment and laboratory support 

  

	 	2.1.2	GTC’s Molecular Biology expertise and facilities 

  

	 	2.1.3	GTC’s Processing and Purification expertise and facilities 

  

	 	2.1.4	GTC’s Regulatory expertise 

  

	 	2.1.5	GTC’s Farm operations, including animal husbandry 

  

	 	2.1.6	GTC’s Program management expertise 

  

	 	2.1.7	GTC’s CMO (“Contract Manufacturing Organization”) management capabilities for the production of clinical and non-clinical material

  

	 	2.1.8	GTC’s CRO (“Contract Research Organization”) management for clinical and non clinical studies (in part or full package including the audited final
reports) 

  

	 	2.1.9	GTC’s capabilities in animal model development and animal in vivo studies 

  

	 	2.1.10	GTC’s capabilities in the of analytical and bio analytical development 

  

	 	2.2	Requisitioned Purchases 

 In the course of GTC’s provision of the Services LFB may requisition and GTC may arrange for the purchase of services or products from third parties, which are billed directly to GTC (“Requisitioned Purchases”). LFB shall
reimburse GTC for the fully billed cost to GTC of any such Requisitioned Purchases. 
  

	 	2.3	Limitations on GTC’s Obligations 

  

	 	2.3.1	GTC need not make available, any Services to the extent that doing so would, in GTC’s sole judgment, unreasonably (i) interfere with the performance by
any GTC employee of services for GTC or otherwise cause unreasonable burden to GTC, or (ii) interfere with the use of or access to by GTC of any equipment, office space or facility or otherwise cause unreasonable burden to GTC.

					
		 	Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote such omissions.

  

	 	2.3.2	 GTC shall have no obligation to provide Services other than those related to or arising out of or in connection with matters which GTC is in a
position to provide by reason of past participation,
involvement or familiarity with such matters and, in addition, which LFB has a reasonable requirement to obtain. 

  

	 	2.3.3	GTC shall not be required to hire any person that GTC would not otherwise hire to provide any of the Services. 

  

	3.	COMPENSATION AND BILLING 

  

	 	3.1	As compensation for the Services, LFB should be invoiced by GTC on the basis of actual costs with a mark up of ************. Actual costs are considered as
actual external costs, and/or actual FTE costs. Actual FTE costs should be calculated and evidenced based upon time sheets and department overheads allocation details. 

  

	 	3.2	LFB shall be billed for the Services on a monthly basis and such amount billed shall be payable to GTC within thirty (30) days after the date of the invoice
for such services 

  

	 	3.3	Out-of-Pocket Expenses 

 Except to the extent otherwise included in the cost of Services, GTC shall be entitled to receive from LFB upon the presentation of invoices therefore, payment for its reasonable out-of-pocket expenses incurred in providing such Services,
including fees and costs incurred by outside parties or affiliates in the provision of Services 
  

	4.	TERM AND TERMINATION 

 This Agreement shall continue in effect for a period of three (3) years following the Effective Date (the “Initial Term”) and, thereafter, on a year-to-year basis unless terminated upon the occurrence of any one of the
following: 
  

	 	4.1	Upon ninety (90) days’ written notice from LFB to GTC at any time during the Initial Term; or 

  

	 	4.2	Upon ninety (90) days’ written notice by either Party to the other Party following the Initial Term 

  

	5.	PROGRESS MEETINGS 

 The
progress of the Services will be discussed during face to face meetings, to be held on an as needed bass. These meetings will be held at GTC’s office in Framingham, MA. All relevant personnel involved from each of the Parties will attend these
meetings 
  

	6.	DEFINITIONS 

 In addition
to the terms defined in the Agreement, the following terms have the meanings set forth below: 
  

	 	6.1	 “Confidential Information” means any scientific, technical, trade or business information possessed, obtained by, developed for or
given to GTC or LFB which is treated by GTC or LFB as confidential or proprietary including, without limitation, Research Materials (defined below), formulations, techniques, methodology, assay systems, formulae, procedures, tests, equipment, data,
reports, know-how, sources of supply, patent positioning, relationships with companies and employees, business plans and business developments, information concerning the existence, scope or activities of any research, development, manufacturing,
marketing or other projects of GTC or LFB, and any other confidential information about or belonging to GTC’s or LFB’s suppliers, licensers, licensees, partners, affiliates, customers, potential customers or others. 

					
		 	Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote such omissions.

  
 “Confidential Information” does not include
information which 
  

	 	(a)	was known to GTC or LFB at the time it was disclosed, other than by previous disclosure by GTC or LFB, as evidenced by GTC’s or LFB’s written records at the
time of disclosure; 

  

	 	(b)	is at the time of disclosure or later becomes publicly known under circumstances involving no breach of this Agreement; 

  

	 	(c)	is lawfully and in good faith made available to GTC or LFB by a third party who did not derive it, directly or indirectly, from GTC or LFB; or 

 

	 	(d)	one of the Parties is legally obligated to do so by a court setting in having proper jurisdiction. 

  

	 	6.2	Examples of Confidential Information 

 For purposes of illustration, the Confidential Information may be contained in various media, including, without limitation, records of research data and observations, records and results of preclinical
and clinical trials, patent applications, regulatory filings, computer programs, manuals, plans, drawings, designs, specifications, supply and customer lists, internal financial data and other documents and records of GTC or LFB, whether or not
labeled or identified as “Confidential” or prepared in full or in part by GTC or LFB. If either Party shall be obligated to provide testimony or records regarding the other Party in any legal or administrative proceeding, then the other
Party shall reimburse the Party providing such records and/or testimony, out-of-pocket costs therefore plus an hourly fee for its employees or representatives equal to the internal fully burdened cost to GTC or such employee or representative.

  

	 	6.3	Research Materials include, without limitation, genes, DNA sequences, plasmids, vectors, expression systems, cells, cell lines, organisms, antibodies, biological
substances, and any constituents, progeny, mutants, derivatives or replications thereof or therefrom, together with all reagents, chemical compounds or other materials developed by or furnished to GTC in connection with GTC’s rendering of the
Services. 

  

	 	6.4	Intellectual Property include, without limitation, ideas, concepts, discoveries, inventions, developments, know-how, trade secrets, techniques, methodologies,
modifications, innovations, improvements, writings, documentation, data, Research Materials and rights (whether or not protectable under state, federal, or foreign patent, trademark, copyright or similar laws) that are conceived, discovered,
invented, developed, created, made or reduced to practice or tangible medium by GTC or under its direction (solely or with others) during the Term and that 

  

	 	(a)	are developed by use of LFB’s equipment, facilities or intellectual property or at LFB’s expense, or 

  

	 	(b)	are directly related to the Services. 

  

	7.	RELATIONSHIP 

  

	 	9.1	Compliance with Policies and Regulations 

 In performing the Services, GTC shall comply with all business conduct, regulatory, and health and safety guidelines or regulations established by LFB or any governmental authority with respect to
LFB’s business. 
  

	8.	PERSONNEL 

  

	 	8.1	GTC Responsibilities 

 GTC shall be solely responsible for any and all salaries, fees, state and federal taxes, withholding, FICA, worker’s compensation or other payments due in respect of the compensation paid to GTC by LFB or by GTC to any employee or
agent employed by GTC. 

					
		 	Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote such omissions.

  

	 	8.2	Agreements with Personnel 

 GTC shall obtain agreements acceptable to LFB with all employees, companies and advisors who participate in rendering the Services which 
  

	 	(a)	impose confidentiality, noncompetition and nonsolicitation obligations on such personnel, and 

  

	 	(b)	effectively vest in GTC any and all rights which such personnel might otherwise have in the results of their work and are adequate to permit OTC to transfer such rights
to LFB hereunder. 

  

	9.	OWNERSHIP OF INTELLECTUAL PROPERTY 

  

	 	9.1	Ownership by GTC 

 All
Developments are “works made for hire” and shall remain the exclusive property of LFB. LFB may use or pursue them without restriction or additional compensation. Should any Intellectual Property be developed and/or any patent applications
be filed, GTC will retain a non-terminable, fully paid up, non-transferable shop right to said Intellectual Property. 
  

	 	9.2	Prompt Disclosure 

 GTC
shall promptly and fully disclose to LFB all Developments. GTC shall keep and maintain complete written records of all Developments and of all work or investigations done or carried out by GTC. These records shall be “works made for hire”
and shall remain the exclusive property of LFB. 
  

	 	9.3	Assignment of Intellectual Property 

 GTC agrees to assign to LFB all of GTC’s right, title and interest in and to any Developments, with the exception of any shop right. During and after the Term, GTC will cooperate fully in obtaining
patent and other proprietary protection for such Developments, all in the name of LFB and at LFB’s cost and expense, and, without limitation, shall execute and deliver all requested applications, assignments and other documents, and take such
other measures as LFB shall reasonably request, in order to perfect and enforce LFB’s rights in the Developments. GTC appoints LFB and its attorney to execute and deliver any such documents on GTC’s behalf in the event GTC fails to do so.

  

	10.	CONFIDENTIALITY, NON-COMPETITION AND NON-SOLICITATION 

  

	 	10.1	Non-Disclosure of Confidential Information 

 GTC shall not directly or indirectly publish, disseminate or otherwise disclose, deliver or make available to any third party any Confidential Information, other than in furtherance of the purposes of
this Agreement, and only then with the prior written consent of LFB. GTC may disclose the Confidential Information to a governmental authority or by order of a court of competent jurisdiction, provided that such disclosure is subject to all
applicable governmental or judicial protection available for like material and reasonable advance notice is given to LFB. 
  

	 	10.2	Non-Use of Confidential Information 

 GTC shall not directly or indirectly use any Confidential Information for GTC’s own benefit or for the benefit of any third party. 
  

	 	10.3	Physical Protection of Confidential Information 

 GTC shall exercise all commercially reasonable precautions to physically protect the integrity and confidentiality of the Confidential Information. GTC will not remove any Confidential Information or
copies thereof from LFB’s premises except to the extent necessary to fulfill the Services, and then only with LFB’s prior consent. 

					
		 	Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote such omissions.

  

	 	10.4	Use of Name 

 Neither
Party shall use the name of the other Party or the names of the employees of the other Party in any advertising or sales promotional material or in any publication without prior written permission of such Party. 
  

	 	10.5	Non-Solicitation 

 During
the period of Services and for a period of one (1) year thereafter, neither Party shall solicit any person who is a Consultant or is employed by either Party or any affiliate or subsidiary of either Party to terminate such person’s
employment by either Party, such affiliate or subsidiary. As used herein, the term “solicit” shall include, without limitation, requesting, encouraging, assisting or causing, directly or indirectly, any such employee or Consultant to
terminate such person’s employment by or consultancy to either Party, affiliate or subsidiary. 
  

	11.	REPRESENTATIONS AND WARRANTIES 

  

	 	11.1	Warranties by Each Party 

 Each Party warrants and represents to the other that: 
  

	 	(a)	that with regard to the information, data, or any other information disclosed under this Agreement that it has the right to disclose this information, whether
considered Confidential Information or not, to the other Party for purposes of this Agreement, 

  

	 	(b)	it has the legal right and power to enter into this Agreement and to perform fully its obligations hereunder, 

  

	 	(c)	it possesses a right, title and interest in any proprietary information to be disclosed and that there is no litigation, action, claim, proceeding or governmental
investigation pending or threatened which may have a materially adverse effect upon the activities and transactions contemplated by this Agreement, 

  

	 	(d)	that with regard to the information, data, or any other information being disclosed for purposes of this Agreement that any confidential information provided does not
infringe or constitute wrongful use of a United States or foreign jurisdiction patent or trade secret right protected under the laws of the United Slates, any state in the United States, or any foreign jurisdiction, and that

  

	 	(e)	it has not made, nor will it make any commitments to the other in conflict with or in derogation of such rights or this Agreement. 

  

	12.	MISCELLANEOUS 

  

	 	12.1	Independent Contractor 

 All Services will be rendered by GTC as an independent contractor and this Agreement does not create an employer-employee relationship or any agency relationship between LFB and GTC. GTC shall have no rights to receive any employee
benefits, such as health and accident insurance, sick leave or vacation which are accorded to regular LFB employees. GTC shall not in any way represent himself to be an employee, partner, joint venturer, agent or officer with or of LFB. 

 

	 	12.2	Insurance 

 GTC shall
secure and maintain in full force and effect throughout the performance of the Services insurance for 
  

	 	(a)	Workman’s Compensation; and 

  

	 	(b)	General Liability having policy limits, deductibles and other terms appropriate to the conduct of GTC business in GIC’s sole and exclusive judgment.

					
		 	Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote such omissions.

  

	 	12.3	Remedies/Indemnities 

 GTC
undertakes to hold harmless, indemnify and defend LFB from and against any and all claims, damages (including loss of life), liability, costs and expense (including interest and professional fees) that may arise from GTC’s sole negligence or
willful misconduct pursuant to this Agreement, issued tasks or any subsequent amendments thereto. 
  

	 	12.4	Service Warranty 

 GTC
warrants to LFB that services provided hereunder will be performed in a workmanlike manner and will substantially conform to the agreed to specifications at the time of performance. Unless otherwise expressly agreed in writing by GTC, GTC warrants
its services for a period of thirty (30) days from the date of performance of services to LFB or its designated receiver of the services. GTC does not warrant results or achievements of services and GTC is not responsible for the work or
activity of any non-GTC employed personnel. GTC makes no other warranty, expressed or implied, with respect to the services. 
  

	 	12.5	Notices 

 Any notice
required or permitted under this Agreement shall be sufficient if in writing and delivered personally or sent by registered or certified mail, if to GTC at: 
 GTC Biotherapeutics, Inc. 
 175 Crossing Boulevard, Suite 410 
 Framingham, MA 01702 
 Attn: Daniel S. Woloshen, Senior Vice President & General Counsel 
 or if to LFB at: 
 LFB Biotechnologies S.A.S. 
 3, avenue des Tropiques 
 Les Ulis, 91940 Courtaboeuf, France 
 Attn: Christian Béchon, President 
  

	 	12.6	Assignment 

 This
Agreement is a personal services agreement, and the rights and obligations hereunder, may not be assigned or transferred by either Party without the prior written consent of the other Party, except that LFB may assign this Agreement to an affiliated
company or in connection with the merger, consolidation or sale of all or substantially all of its assets. 
  

	 	12.7	Severability 

 In the
event that any one or more of the provisions contained in this Agreement shall, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of
this Agreement, and all other provisions shall remain in full force and effect. If any of the provisions of this Agreement are held to be excessively broad, it shall be reformed and construed by limiting and reducing it so as to be enforceable to
the maximum extent permitted by law. 
  

	 	12.8	Force Majeure 

 Either
Party shall be excused from performing its obligations under this Agreement if its performance is delayed or prevented by any event beyond such Party’s reasonable control, including but not limited to, acts of God, fire, explosion, weather,
disease, war, insurrection, civil strife, riots, government action, terrorist acts, or power failure, provided that such performance shall be excused only to the extend of and during such disability. Any time specified for completion of

					
		 	Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote such omissions.

  
 
performance of the Agreement falling due during or subsequent to the occurrence of any or such events shall be automatically extended for a period of time equal to the period of such disability.
GTC will promptly notify LFB if, by reason of any of the events referred to herein, GTC is unable to meet any such time for performance specified in the Agreement. If any part of the Agreement is invalid as a result of such disability, GTC will,
upon written request from LFB, but at LFB’s sole cost and expense, repeat that part of the Agreement affected by the disability. 
  

	 	12.9	Entire Agreement 

 This
Agreement constitutes the entire agreement of the Parties with regard to its subject matter, and supersedes all previous written or oral representations, agreements and understandings between GTC and LFB. 
  

	 	12.10	No Modification 

 This
Agreement may be changed only by a writing signed by both Parties. 
  

	 	12.11	Applicable Law 

 This
Agreement shall in all events and for all purposes be governed by, and construed in accordance with, the laws of The Commonwealth of Massachusetts. 
 IN WITNESS WHEREOF, LFB and GTC have signed this Agreement as of the Effective Date 
  

			
	GTC BIOTHERAPEUTICS, INC.	  	LFB BIOTECHNOLOGIES S.A.S.
		
	 By: /s/ Geoffrey F. Cox                

	  	By: /s/ Christian Béchon            
		
	 Print Name: Geoffrey F. Cox        
	  	By: Christian Béchon                
		
	 Title:
Chairman/CEO                    
	  	Title:
CEO                                
		
	 Duly Authorized
	  	Duly Authorized

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}]]